Join the Hepatitis B group to help and get support from people like you.
Hepatitis B News
Related terms: Chronic Hepatitis B, Hepatitis B, Chronic, HBV
Thousands of Hospital Patients in Oregon May Have Been Exposed to Hepatitis, HIV
FRIDAY, July 12, 2024 – After an anesthesiologist may have exposed thousands of people treated at several hospitals in Oregon to hepatitis and HIV, those patients are being advised to get tested for...
Chronic Hepatitis B Virus Is Undertreated
FRIDAY, May 3, 2024 – Underassessment and undertreatment of chronic hepatitis B virus (HBV) is seen globally, according to a study published online May 1 in the Journal of Hepatology. Sahith ...
Prevalence of Hepatitis Delta High in Hepatitis B Surface Antigen Chronic Carriers
THURSDAY, April 4, 2024 – The prevalence of hepatitis delta virus (HDV) is high in hepatitis B surface antigen (HBs Ag) chronic carriers detected through annual screenings, according to a study...
FDA Expands Indication for Gilead's Vemlidy (tenofovir alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
March 28, 2024 – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug...
Antivirals Aid HBeAg-Negative Chronic Hepatitis B Patients
WEDNESDAY, Jan. 3, 2024 – Continuous nucleos(t)ide analog treatment is effective in lowering the risk for liver cirrhosis in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients, ...
Revaccination Suggested for Hep B Vaccine Nonresponders After Hep C Cure
MONDAY, Sept. 18, 2023 – Patients with chronic hepatitis C virus (HCV) who do not respond to hepatitis B virus (HBV) vaccine should undergo revaccination after HCV treatment and eradication,...
U.S. Food and Drug Administration Approves Vemlidy (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Approval Expands on Previous FDA Approval of Vemlidy in Adults Living With This Chronic Liver Disease Efficacy and Safety of Once-Daily Vemlidy Demonstrated in Individuals 12 Years of Age and Older ...
Dynavax Announces FDA Approval of Heplisav-B for Prevention of Hepatitis B in Adults
BERKELEY, CA – (Marketwired) – November 9, 2017 – Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved Heplisav-B...
FDA Approves Gilead’s Vemlidy (tenofovir alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy (tenofovir...
FDA Medwatch Alert: Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating
ISSUE: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain...
FDA Medwatch Alert: Recombivax HB (Hepatitis B Vaccine (Recombinant)) Adult Formulation by Merck Sharp and Dohme Corp.: Recall - Potential For Cracked Vials
ISSUE: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (Merck), initiated this voluntary recall due to the potential for a limited number of cracked vials to be present in the lot....